NDAINJECTIONINJECTABLE
Approved
Aug 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sulfadiazine sodium is an injectable sulfonamide antibiotic approved in 1941 for treatment of bacterial infections. It is administered intravenously and works by inhibiting bacterial folate synthesis. This is a legacy antibiotic with narrow modern use in specialized infection settings.
LOE Approaching
As an 80+ year old product approaching loss of exclusivity with minimal modern market presence, the commercial team is likely small and focused on niche hospital/specialty settings.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on sulfadiazine sodium offers limited career advancement opportunity given zero linked job openings and minimal commercial momentum. This is primarily a legacy product maintenance role suitable for cost management, specialty hospital relationships, or manufacturing expertise rather than growth or innovation-focused careers.
Brand ManagerField Sales Representative
Worked on SULFADIAZINE SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.